$-0.02
(Market cap
$7 Mln
Revenue (TTM)
$13 Mln
P/E Ratio
--
P/B Ratio
8.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-7.8 %
-
ROCE
-- %
-
Industry P/E
28.71
-
EV/EBITDA
-0.8
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-4.8
-
Face value
--
-
Shares outstanding
9,359,130
10 Years Aggregate
CFO
$-192.73 Mln
EBITDA
$-218.59 Mln
Net Profit
$-253.56 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Adamis Pharma (ADMP)
| -95.9 | -12.9 | -64.0 | -95.2 | -78.7 | -69.9 | -49.0 |
|
BSE Sensex*
| -11.1 | -2.1 | -8.9 | -7.5 | 6.6 | 9.1 | 11.4 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Adamis Pharma (ADMP)
| -72.1 | 25.7 | -30.7 | -68.9 | -48.7 | 39.7 | -41.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Adamis Pharma (ADMP)
|
0.5 | 7.3 | 12.7 | -11.6 | -118.9 | -- | -- | 8.6 |
| 11.9 | 3,805.9 | 3,045.9 | 122.4 | 13.8 | -- | 32.2 | 105.4 | |
| 41.0 | 5,251.4 | 1,029.0 | 133.3 | 14.5 | 32.7 | 38.3 | 12.7 | |
| 227.7 | 11,139.5 | 708.2 | -188.3 | -25.6 | -293.5 | -- | 204.8 | |
| 66.1 | 12,668.3 | 566.0 | -725.9 | -89.0 | -- | -- | 123.7 | |
| 56.4 | 5,496.4 | 769.1 | 47.9 | 5.4 | 7.5 | 146.3 | 8.8 | |
| 13.6 | 11,417.2 | 353,471.6 | 45,087.2 | 16.1 | 12.8 | 25.8 | 2.8 | |
| 19.9 | 10,808.1 | 4,893.0 | -242.0 | -1.5 | -3.7 | -- | 1.8 | |
| 213.2 | 4,418.7 | 274.5 | 153.6 | 76.6 | 15.8 | 28.7 | 4.4 | |
| 56.9 | 4,724.8 | 158.3 | -68.9 | -29.3 | -113 | 312.5 | 84.0 |
Shareholding Pattern
View DetailsAbout Adamis Pharma (ADMP)
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine... injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California. Read more
-
Co-Founder, CEO, Pres & Director
Mr. David J. Marguglio
-
Co-Founder, CEO, Pres & Director
Mr. David J. Marguglio
-
Headquarters
San Diego, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Adamis Pharma (ADMP)
What is the current share price of Adamis Pharma (ADMP) Today?
The share price of Adamis Pharma (ADMP) is $0.49 (NASDAQ) as of 09-Nov-2023 09:30 EDT. Adamis Pharma (ADMP) has given a return of -78.7% in the last 3 years.
What is the current PB & PE ratio of Adamis Pharma (ADMP)?
Since, TTM earnings of Adamis Pharma (ADMP) is negative, P/E ratio is not available.
The P/B ratio of Adamis Pharma (ADMP) is 8.62 times as on 09-Nov-2023, a 44 premium to its peers’ median range of 6.00 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.01
|
-0.45
|
|
2021
|
-0.04
|
0.05
|
|
2020
|
-0.92
|
13.02
|
|
2019
|
-0.02
|
0.02
|
|
2018
|
-0.04
|
0.03
|
What is the 52 Week High and Low of Adamis Pharma (ADMP)?
The 52-week high and low of Adamis Pharma (ADMP) are Rs -- and Rs -- as of 17-May-2026.
What is the market cap of Adamis Pharma (ADMP)?
Adamis Pharma (ADMP) has a market capitalisation of $ 7 Mln as on 09-Nov-2023. As per SEBI classification, it is a company.
Should I invest in Adamis Pharma (ADMP)?
Before investing in Adamis Pharma (ADMP), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.